A method for manufacturing a functional material that contains plasmalogen, the method including treating an animal tissue containing plasmalogen with protease, and extracting the animal tissue treated with protease with an extraction liquid containing ethanol.

The present disclosure relates to the treatment of diseases or conditions in a subject, including skin conditions or diseases, comprising applying to the skin of the subject a first composition comprising Spongilla, and a second composition comprising a therapeutically effective amount of one or more drugs, wherein said drugs are selected from a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. Further provided are such methods wherein the one or more biological macromolecules is selected from a recombinant protein, a fusion protein, an antibody, a monoclonal antibody, a humanized monoclonal antibody, a bivalent antibody, an antibody fragment, an antibody-drug conjugate, a Fc fragment, a Fab fragment, a Fab′ fragment, a (Fab′)2 fragment, a Fv fragment, and a scFv fragment.

The present disclosure relates to the treatment of diseases or conditions in a subject, including skin conditions or diseases, comprising applying to the skin of the subject a first composition comprising Spongilla, and a second composition comprising a therapeutically effective amount of one or more drugs, wherein said drugs are selected from a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. Further provided are such methods wherein the one or more biological macromolecules is selected from a recombinant protein, a fusion protein, an antibody, a monoclonal antibody, a humanized monoclonal antibody, a bivalent antibody, an antibody fragment, an antibody-drug conjugate, a Fc fragment, a Fab fragment, a Fab′ fragment, a (Fab′)2 fragment, a Fv fragment, and a scFv fragment.

The present disclosure relates to the treatment of diseases or conditions in a subject, including skin conditions or diseases, comprising applying to the skin of the subject a first composition comprising Spongilla, and a second composition comprising a therapeutically effective amount of one or more drugs, wherein said drugs are selected from a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. Further provided are such methods wherein the one or more biological macromolecules is selected from a recombinant protein, a fusion protein, an antibody, a monoclonal antibody, a humanized monoclonal antibody, a bivalent antibody, an antibody fragment, an antibody-drug conjugate, a Fc fragment, a Fab fragment, a Fab′ fragment, a (Fab′)2 fragment, a Fv fragment, and a scFv fragment.

The present disclosure relates to the treatment of a skin condition in a subject, including but not limited to hyperhidrosis, comprising applying to the skin of the subject a first composition derived from one or more sponges, and a second composition comprising one or more botulinum toxins. Also provided are compositions for use in the treatment of a skin condition in a subject, including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein (a) the first composition comprises Spongilla; and (b) the second composition comprises one or more botulinum toxins. Also provided are kits, including kits for the treatment of a skin condition in a subject including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more botulinum toxins.

The present disclosure relates to the treatment of a skin condition in a subject, including but not limited to hyperhidrosis, comprising applying to the skin of the subject a first composition derived from one or more sponges, and a second composition comprising one or more botulinum toxins. Also provided are compositions for use in the treatment of a skin condition in a subject, including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein (a) the first composition comprises Spongilla; and (b) the second composition comprises one or more botulinum toxins. Also provided are kits, including kits for the treatment of a skin condition in a subject including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more botulinum toxins.

This is to provide a useful application of plasmalogen, which is not yet known.

A composition contains plasmalogen for enhancing a verbal memorization ability and/or a visual memorization ability.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

The present invention relates to novel pyridine nucleoside compounds, Neopetroside A (NPS A) and Neopetroside B (NPS B) obtained by fractionating an extract of Neopetrosia sp. which is a marine sponge, with ethanol, into n-butanol (n-BuOH). When the NPS A was treated with myocardial cells, it activates oxidative phosphorylation, basal and mitochondrial respiration induced by ATP and ATP synthesis, and stimulates the glycolysis activity and when the NPS A was treated with an ischemic reperfusion injury model, the left ventricular pressure injured by ischemic reperfusion was recovered and the size of myocardial injury site was significantly reduced and as a result, can be provided as the pharmaceutical composition for preventing or treating ischemic heart disease or the health functional food for preventing or improving the same.